ProQR Therapeutics NV
F:0PQ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
ProQR Therapeutics NV
F:0PQ
|
NL |
|
Achieve Life Sciences Inc
NASDAQ:ACHV
|
US |
|
I
|
Intel Corp
BMV:INTC
|
US |
|
G
|
Gobarto SA
WSE:GOB
|
PL |
|
F
|
First Advantage Corp
NASDAQ:FA
|
US |
|
Agora Inc
NASDAQ:API
|
US |
|
U
|
Ulta Beauty Inc
XMUN:34U
|
US |
|
J
|
Jasmine International PCL
SET:JAS
|
TH |
|
VSE Corp
F:VS3
|
US |
Intrinsic Value
Is 0PQ undervalued or overvalued?
See the intrinsic value estimate for 
ProQR Therapeutics NV and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
0PQ looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with 0PQ’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What ProQR Therapeutics Does
ProQR Therapeutics is a biotech company that designs RNA-based medicines for people with rare genetic diseases. Instead of making traditional small-molecule drugs or antibodies, it works on therapies that try to correct problems caused by faulty genes at the RNA level, which is the step between DNA and protein production. Its main work is in developing treatments that can help cells make the right protein again.
- Headquarters
- Netherlands NL
- Employees
- 187
- IPO date
- Sep 18, 2014
Revenue & Expenses Breakdown
ProQR Therapeutics NV
Earnings Waterfall
ProQR Therapeutics NV
The intrinsic value for ProQR Therapeutics NV (0PQ) under the Base Case is hidden EUR.
Compared with the current market price of 1.173 EUR, the stock appears hidden.